Rosenblatt Russell E, Tafesh Zaid H, Halazun Karim J
Division of gastroenterology and hepatology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
Department of surgery, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.
Transl Gastroenterol Hepatol. 2017 Nov 21;2:95. doi: 10.21037/tgh.2017.10.04. eCollection 2017.
Since the advent of the Milan criteria in 1996 and its widespread adoption for selection of patients with hepatocellular carcinoma (HCC) who would benefit from transplant, there has been an extensive hunt for the ideal clinical biomarker to predict HCC recurrence. This is because Milan lack does not include tumor biology indices and recurrence rates remain in the 15-20% range worldwide. While a 'silver-bullet' biomarker has not been found, several useful inflammatory markers have been identified and used in scoring systems that supersede Milan in their ability to predict HCC recurrence post liver transplantation (LT). In this review, we aim to summarize the role of inflammatory markers paly in the selection of HCC patients awaiting LT.
自1996年米兰标准问世并被广泛应用于筛选有望从移植中获益的肝细胞癌（HCC）患者以来，人们一直在广泛寻找预测HCC复发的理想临床生物标志物。这是因为米兰标准未纳入肿瘤生物学指标，且全球范围内复发率仍在15%-20%之间。虽然尚未找到“万灵药”式的生物标志物，但已确定了几种有用的炎症标志物，并将其用于评分系统，这些评分系统在预测肝移植（LT）后HCC复发的能力方面超越了米兰标准。在本综述中，我们旨在总结炎症标志物在筛选等待LT的HCC患者中所起的作用。
